TECHNOLOGICAL ASPECTS OF MANUFACTURING THE FIRST KAZAKHSTAN SEASONAL INFLUENZA SPLIT VACCINE
Main Article Content
Authors
N.N. Assanzhanova
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
Zh.K. Kydyrbayev
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
Sh.Zh. Ryskeldinova
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
M.M. Kassenov
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
B.M. Khairullin
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
K.K. Tabynov
Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambylskaya oblast, 080409, Republic of Kazakhstan
Abstract
The development of the technological stages of manufacturing an experimental, inactivated seasonal trivalent influenza split vaccine in the Republic of Kazakhstan is presented here. Master and working seed lots of the A/NIBRG-121хр (H1N1), A/NYMC X-217 (H3N2), and B/NYMC BX-49 (type B) strains were obtained for manufacturing a seasonal influenza vaccine. The purification and concentration of the three influenza virus strains were optimised and achieved by flow-through centrifugation on a linear sucrose gradient (0-60%). The optimal modes of inactivation were achieved using β-propiolactone at a final concentration of 0.1% and the subsequent splitting was carried out using the detergents Triton X-100 and Tween-80. The purified and inactivated virus concentrates were subjected to technological quality control at each production stage, as well as to stability testing. Quality control was carried out in accordance with regulations approved by the biological industry for the production and vaccines control for health care. For the first time in the Republic of Kazakhstan, a pilot batch of seasonal trivalent influenza split vaccine was produced from the NIBRG-121xp, A/NYMC X-217 (H3N2), and B/NYMC BX-49 strains. Quality-control results demonstrated that the prepared batch of vaccine meets National Pharmacopeia of Republic of Kazakhstan and European Pharmacopeia requirements and is suitable for further clinical trials.
Keywords
seasonal influenza virus, cultivation, purification and concentration, inactivation, splitting, stabilization, vaccine
Article Details
References
Bayer V.E., Palash A.M., Osterhaus A.D. Sravnenie immunogennosti i reaktogennosti sub"edinichnykh, tsel'novirionnykh i rasshcheplennykh vaktsin protiv grippa. Russkii Meditsinskii Zhurnal, 2000, vol. 8, no. 5, pp. 17-23.
Beyer W.E.P., Nauta J.J.P., Palache A.M. et al. Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. Vaccine, 2011, vol. 29, no. 34, pp. 5785-5792.
Bresson J.L., Perronne C., Launay O. et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 2006, vol. 367, pp. 1657-1664.
Robert W., Frenck Jr., Belshe R. et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine, 2011, vol. 29, no. 34, pp. 5666-5674.
WHO Expert Committee on Biological Standardization: fifty-fourth report. WHO technical report series; 927. Annex 3. Recommendations for the production and control of influenza vaccines (inactivated). Geneva, Switzerland, 2003, pp. 99-135.
Akzhunusova I., Assanzhanova N., Tabynov K., et al. Optimization of influenza A and B viruses cultivation conditions for preparation of trivalent seasonal influenza split vaccine. International Journal of Pharmaceutical Sciences and Research, 2015, vol. 6, no. 6, pp. 1000-1007.
Metodicheskie ukazaniia MU 3.3.2.1758-03 «Metody opredeleniia pokazatelei kachestva immunobiologicheskikh preparatov dlia profilaktiki i diagnostiki grippa»: utv. Glavn. gosud. san. vrachom RF 28 sentiabria 2003 g. – 31 p.
Goldstein S., Blecher M. The spectrophotometric assay for polyethoxy nonionic detergents in membrane extracts: a critique. Anal. Biochem., 1975, vol. 24, pp. 130-135.
Pat. 2503719 RU Int. Cl. 7: C12N7/02 A61K39/145 A61K39/12. Method of virus treatment by ultracentrifugation in sugar concentration gradient (versions): Grill'berger L., Rajter M., Mundt V., Mitterer A., Shafkhauzer Kh.; Proprietor(s) Baxster International Inc. (US), Baxter Healthcare С.А. (Ch); appl. 30.04.08, publ. 10.01.14; Bul. №1; priority 04.05.07, №60/927692 (US).
Tosh P.K., Jacobson R.M., Poland G.A. Influenza vaccines: From surveillance through production to protection. Mayo Clinic Proceedings, 2010, vol. 85, no. 3, pp. 257-273.
Lagacé-Wiens P.R.S., Rubinstein E., Gumel A. Influenza epidemiology-past, present, and future. Critical Care Medicine, 2010, vol. 38, no. 4, pp. 1-9.
Tabynov K., Kydyrbayev Zh., Sansyzbay A. et al. Immunogenic and Protective Properties of the First Kazakhstan Vaccine against Pandemic Influenza А (Н1N1) pdm09 in Ferrets. Virologica Sinica, 2012, vol. 6, no. 27, pp. 345-352.
State Pharmacopoeia of the Republic of Kazakhstan. Almaty, Zhibek Zholy, 2008, vol. 1, 592 p.
European Pharmacopoeia EP 5.0-01/2005-0158 Monograph Influenza vaccine (split virion, inactivated).